Cleaning Validation in the Pharmaceutical Industry

Size: px
Start display at page:

Download "Cleaning Validation in the Pharmaceutical Industry"

Transcription

1 Cleaning Validation in the Pharmaceutical Industry By Mowafak Nassani, Ph.D. INTRODUCTION Cleaning validation in the pharmaceutical industry has been a topic of ever-increasing interest and scrutiny in recent Food and Drug Administration (FDA) inspections. The validation of procedures used to clean the equipment employed during the various steps of a manufacturing process is a clear requirement of current Good Manufacturing Practice (cgmp). As such, FDA inspectors now expect to see a functioning cleaning validation program with appropriate documentation in place during their inspections. The requirement that equipment be clean before being used is not a new concept. The equally important requirement that it also be sanitary is many times obfuscated by the word, clean. In response to the often-asked question what is clean, the FDA published a guidance document: the 2004 FDA Guide to Inspections Validation of Cleaning Processes. The FDA s guide to inspections, which intended to cover equipment cleaning for chemical residues only, includes: 1. FDA expects firms to have written procedures [Standard Operating Procedures (SOPs)] detailing the cleaning processes FDA expects firms to have written general procedures on how cleaning processes will be validated. 3. These procedures will address who is responsible for performing 38 Institute of Validation Technology

2 and approving the validation study, the acceptance criteria, and when revalidation will be required. 4. FDA expects firms to conduct the validation studies in accordance with the protocols and to document the results of studies. 5. Besides assuring chemical cleanliness, the microbiological aspects of equipment cleaning should be considered. This consists largely of preventive measures 6. Determine the specificity and sensitivity of the analytical method used to detect residuals or contaminants. 7. The firm should challenge the analytical method in combination with the sampling method(s) used to show that contaminants can be recovered from the equipment surface and at what level Direct sampling (e.g., with swabs) is most desirable, although rinse sampling may be satisfactory. OBJECTIVES The objectives of this article are to establish a broad basis for cleaning validation policy and programs, and to determine the requirements, procedures, acceptance limits, and working papers needed to support this vitally important activity. Cleaning Validation Protocol Cleaning validation protocols should be developed, approved, and executed in accordance with the SOPs covering these activities in place at the time. A typical cleaning validation protocol should consist of Objective, Sampling and Testing Methodologies, and Acceptance Criteria sections. Objective This section defines the intention and scope of the cleaning validation exercise. Additionally, it will include information such as equipment names, identification numbers, the name(s) and type(s) of product being cleaned from the equipment, and the individual components of the product and equipment under investigation. Sampling and Testing Methodologies This section should typically include a step-by-step explanation of sampling techniques and requirements, as well as the specific analytical procedures to be used in the analysis of those samples. It should specify which laboratories are to be involved in the testing and any precautions to be taken throughout the validation exercise. Cleaning Validation 39

3 A visual check should be incorporated into the cleaning assessment. The sampling technique chosen to evaluate the effectiveness of the cleaning procedure should be swabbing, the fluid rinse of samples, or a combination of both methods. The following sampling methods provide various levels of assurance concerning cleaning: Visual inspection Active product contact parts of the equipment are individually examined (wherever possible) for cleanliness. This visual inspection allows the early localization and identification of any inadequacies in the cleaning procedure. Qualitative dependent upon inspector and item sampled. Subjective dependent upon inspector and item sampled. Rinse water sampling and analysis According to 2004 FDA Guide to Inspections Validation of Cleaning Processes: Two advantages of using rinse samples are that a larger surface area may be sampled, and inaccessible systems or ones that cannot be routinely disassembled can be sampled and evaluated. Analysis can be quantitative, using ph, conductivity, particle count, microbial count, Total Organic Carbon (TOC) determination, spectrophotometry, bioassays, or limulus amebocyte lysate for pyrogens. Recovery factor is uncertain; it involves dilution. Surface sampling and analysis Removes adherent materials. Analysis can be quantitative. Precise definition of the area sampled is required. Surface sampling from coupons Quantitative. Depends on whether coupons are equivalent to the surface of interest. Requires removing coupons from the system. Method Selection Whenever possible, each piece of equipment should be dismantled into its individual components after cleaning and each part should be individually tested for cleanliness. In this manner, any inadequacies in the cleaning process will be more readily identified and localized. 40 Institute of Validation Technology

4 It may not be practical or desirable to dismantle large or Clean In Place (CIP) equipment. Regardless, validation sampling and testing should commence as soon as possible after the cleaning process is complete to reduce the chance for contamination by outside sources. Equipment that has just been cleaned should be covered immediately by appropriate means to protect it from any contamination. Solvents Aqueous or organic solvents used in the cleaning procedure, should be sufficient to remove residues, and at the same time, should be minimized to reduce the risk of reaction with or damage to the equipment, or the over-dilution of the residue and the resultant loss of analytical sensitivity. Samples should be collected in clean or sterile containers. Sterile containers are suitable for this intended use. All validation samples must be properly labeled with complete information regarding the source of the sample, sampler s name, sampling date, reference number, product name, and the part of equipment from which the sample has been collected. A sample of the rinse or swabbing solvent should always be included with the actual test samples to serve as a reagent blank for any chemical or microbiological determination when required. All types of samples, physical, chemical, or microbiological, should be collected according to a written procedure and using techniques, reagents, equipment, and containers appropriate to the type of testing to be performed. Only trained personnel should perform the collection of these samples. The environmental effectiveness of cleaning procedures should be assessed by surface sampling of non-product contact surfaces (e.g.: floors, walls, air ducts, exterior equipment surfaces, etc.). Samples should be collected and analyzed for potential contamination. Cleaning Validation 41

5 Sampling Methods The sampling method selection for cleaners, involves choosing between rinse water sampling, swabbing surfaces, coupon sampling, or placebo sampling. Rinse water sampling involves taking a sample of an equilibrated post-final rinse that has been re-circulated over all surfaces. Rinse samples should be correlated to a direct measuring technique such as swabbing. Figure 1 Swabbing involves using a wipe or swab that is moistened with high purity water, such as Water-for-Injection (WFI) that is typically wiped over a defined area in a systematic multi-pass way always going from clean to dirty areas to avoid recontamination (e.g.: 10 cm side by side strokes vertically, 10 cm horizontally, and 10 cm each with the flip side of the swab in each diagonal direction). For TOC analysis, very clean swabs or wipes and sample vials should be used. (All of these are commercially available). The amount of residue is known to be uniformly distributed on the smooth surfaces of equipment parts. Also, the most difficult to clean or worstcase areas of the equipment should be identified and specifically targeted for sampling whenever possible. Worst-Case Determination Table Product Active Material Batch Size Solubility * Cleaning Ease** Maximum allowable daily amount of active in total daily unit dose of next product A B C * Given number to describe solubility: 1, 2, 3, 4, 1 is more soluble than 2 in the same solvent, etc. ** Given number to describe cleaning ease: 1, 2, 3, 4, 1 is easier to clean than 2 under the same conditions and procedure, etc. 42 Institute of Validation Technology

6 Residue Detection Selecting a method to detect cleaner residues can involve specific methods for specific cleaner ingredients such as: High Performance Liquid Chromatography (HPLC), ion selective electrodes, flame photometry, derivative UltraViolet (UV) spectroscopy, Thin Layer Chromatography, enzymatic detection, and titration. It can also involve non-specific methods that detect the presence of a blend of ingredients such as: TOC, ph, and conductivity. The FDA prefers specific methods, but will accept non-specific methods with adequate rationales for their use. For investigations of failures or action levels, a specific method is usually preferable. Analytical Evaluation Analytical validation of the cleaning procedure should be performed after the approval of visual inspection (absence of stains or any materiel residue). The specificity, sensitivity, and percentage of recovery of the test method should be adequate to meet acceptance criteria. Total number of units dose per day Unit dose weight Number of doses made by one batch Highest daily dose Active material present in one batch Residual limit compared to worst-case Cleaning Validation 43

7 For the swab method it may be necessary to determine: The percentage recovery of the swab extraction procedure. The effectiveness of the swab at recovering residues from equipment parts surface. The interference of swab materials in the analysis. For the rinse solution method it may be necessary to determine: The percentage recovery of the rinse solution extraction procedure. The effectiveness of the rinse solution at recovering residues from equipment parts surfaces. The interference of the rinse solution in the cleaning procedure and analysis. A correction for recovery efficiency in calculations for acceptable residue levels. Percentage Recovery = 100 x Sample Concentration / Standard Concentration The percentage recovery is important because it will be applied when evaluating the final residual concentration according to the relation: Percentage of actual amount of residual = Calculated Amount x Percentage Recovery It is very difficult to establish acceptable fixed limits for recovery percentage due to the individual difference in solubility of residues, the solvent used, and the nature of the manufacturing surfaces. The following three factors contribute to the difficulty of establishing fixed limits for the recovery percentage: 1. The residues behavior toward the solvent used. 2. The solvent used. 3. The nature of the manufacturing surfaces. Some products such as proteins, for example, have a very low solubility, so the percentage recovery may be as low as 10 20%. For soluble residue, a higher percentage recovery should be expected. In general we can expect an ideal percentage recovery that falls between 60% and 90%. It is very important to continuously develop the sampling and swabbing methods and reproducibility to improve percentage recovery values. Microbiological Cleaning Considerations 44 Institute of Validation Technology

8 All equipment that comes in contact directly with raw material - intermediate as well as final product - must be considered for inclusion, because of its potential to act as a possible source for microbiological contamination. In addition, the facilities must be considered for the level of microbiological contamination appropriate to the area classification. Microbiological samples should be collected prior to and throughout the cleaning procedure to assist in selection and confirmation of the efficacy of disinfectants and detergents. Microbiological cleanliness is assessed as < 200 cfu / 100 cm 2 for non-sterile production. It is important to determine the type of organism present. It is necessary to demonstrate the absence of pollution indicator organisms such as, Escherichia coli, Salmonella spp, and Pseudomonas aeroginosa, from all locations monitored. It is necessary, as well, to ensure that high levels of other microbial flora do not mask these organisms. Within sterile production, attention must be paid to the number of organisms present rather than their type. The level of microbiological contamination of the rinse water should be 10 cfu / 100 ml. Sampling is repeated three times during the validation. Worst-Case Determination Worst-case determination of cleaning validation is a crucial step in defining contamination limits and in cleaning procedure efficacy. A worst-case determination study should be based on: active product solubility; active product toxicity; smallest batch size that can be manufactured using the equipment concerned; the maximum daily dose of this product; the number of dosages that can be made from next batch (contaminated); the product in its largest available tables mass, or in case of ampoules or vials, the largest available filling volume, and in both cases, the highest daily dose; the total area with which the product comes into contact; the area of one tablet or the volume of one individual fill; and the total amount of residual contaminant (see Figure 1). After completing the worst-case determination table, we can easily identify the product representing this case (A, B, or C). The table Cleaning Validation 45

9 should list all products to be manufactured in the same equipment whatever the chemical and bioactivity types of actives. Acceptance Criteria In determining the final acceptance criteria for a cleaning validation exercise, the calculation of the acceptable level of contaminant in the next product maximum therapeutic patient dose is of primary importance. Acceptance criteria are established by considering the contaminant type, the facility, and the risk to the operator, product, and patient. More stringent acceptance criteria are required in the case of highly biologically active materials compared to some excipients. Facilities that produce product based on a single chemical entity (dedicated facility) shall not be subjected to as stringent a standard as multi-purpose facilities. Dedicated areas offer a low-risk potential, whereas a multiproduct area tends toward a higher risk of contamination. The use of automated cleaning process will tend toward more reproducible results when compared with manual systems. When a number of materials are potential contaminants, consider which items are to be removed by the cleaning process (e.g.: chemical intermediates, active ingredient, detergent, excipient, colour, flavour, degradation product, micro-organism, endotoxin, particulates, lubricants, residual solvents, moisture, etc.). The equipment should demonstrate the absence of obvious liquid, liquid and solid residues, and be free from any noticeable off odor. A worst-case approach should be adopted and the cleaning procedure should be validated for the least soluble and most difficult to clean active or finished product as well as any residual cleaning agent. When more than one piece of equipment or stage is involved in the processing, the cumulative effect of each should be taken into consideration. Microbiological acceptance criteria for cleaning procedures should be established based on product type. There may be a requirement for all or certain specific microorganisms to be absent dependent upon product type. Acceptance criteria should be justified in a rational, written, approved, document prior to the commencement of the validation exercise. Worst-case criteria are to be calculated for a product group manufactured in common equipment and then are to be applied to a selected reference product. Adding a new product formulation to the existing product group may act on the existing acceptance criteria. Also, if the product is less soluble than the existing reference product, then the new product can become the reference product and full cleaning validation must be performed. The new 46 Institute of Validation Technology

10 product should become a stand alone case when the cleaning method required is not suitable for other products. A safety factor of not more than 1 / 1000 (0.1%) of the active under investigation (contaminant) found in a single unit of the lowest dosage form of the next product should remain in the equipment after the cleaning procedure. A list summarizing the batch size of products manufactured through the same equipment should be prepared in order to determine the smallest batch size. This is an important step to calculate the carryover limit. The calculation of acceptance criteria should be based on the following parameters: Residual limit of active (contaminant) expressed in mg / cm 2 : R 1/ 1000 of concentration of active (contaminant) per dose units: L Maximum allowable number of doses per day of next product (contaminated): D Smallest batch size in mg: B Concentration of active in unit dose of next product (contaminated) or the number of total dose units manufactured: C Total surface area of equipment parts in contact with the product (contaminant) expressed in cm 2 : T Surface swabbed in cm 2 : S Thus, the residual limit in the cleaned equipment of active (contaminant) mg / cm 2 is calculated as follows: R mg / cm 2 = L / D x B / C x S / T For example: Concentration of active (contaminant) per dose unit = 30 mg Maximum allowable number of doses per day of next product (contaminated) = 4 Units Batch size (smallest) in mg = 50 x 10 6 Concentration of active in unit dose of next product (contaminated) or the number of total dose units manufactured = 200 mg Cleaning Validation 47

11 Total surface area of equipment parts in contact with the product (contaminant) expressed in cm 2 = cm 2 Surface swabbed in ccm 2 = 100 cm 2 Residual limit of active (contaminant) in mg / cm 2 = 30 x 1/1000 / 4 x 50 x 106 / 200 x100 / Residual limit of active (contaminant) in the equipment after cleaning = 4.17 mg / cm 2 For the automated systems and where rinse is used and rinse volumes are known, the following equation could be used taking into consideration the total volume of final rinse in ml V: R mg / ml = L / D x B / C x 1 / V The active (contaminant) carryover from product A to the next product B (contaminated) per unit dose is calculated as follows: For example, the concentration of active (contaminant) A per unit dose is 2 mg per day. Based on a safety factor of not more than 1 / 1000 (0.1%) of the active under investigation (contaminant) found in a single unit of the lowest dosage form of the next product, we can say: The limit of concentration of active A found in total (standard) daily dose units of next (contaminated) product B is: 1 / 1000 x 2 mg = mg or 2 µg Supposing that the total amount of contaminant product A found in the total product contacting parts of the equipment after cleaning is 9 mg (9000 µg). The next smallest batch size worst-case (contaminated) B is 100 Kg and B unit dose weight (tablet weight for example) is 90 mg. The total allowable daily dose of B is three doses. The concentration of active contaminant A carried over to unit dose of product B is calculated: Contaminant µg / mg = 9000 µg / 100 x 10 6 Contaminant µg / mg = 9 x 10-5 Contaminant µg / Unit dose = 9 x 10-5 x 90 Contaminant µg / Unit dose B = Institute of Validation Technology

12 Contaminant µg / Total Daily dose B = x 3 Contaminant µg / Total Daily dose B = The active (contaminant) A carried over to total daily units dose of product B (contaminated) is inferior to the established limit of 2 µg. Another more conservative acceptance criteria limit could be adopted. It considers that no more than 5 ppm from any active product can be left on any part of equipment for potential carryover to next product. This conservative limit could not be applied for all types of products of pharmaceutical forms. An acceptance limit of 5 ppm could be applied for products having a bioactivity or strength less than 10 mg per unit dose highly bioactive or for products having a high level of toxicity. The main inconvenience of the application of this limit is related to the analytical method Limit of Detection (LoD or LD) and to equipment sensitivity in detecting this value. Detergent and cleaning agents should be treated by using the safety factor of 1 / 1000 of LD 50 value or less than 10 ppm, whichever is the lowest. Another assessment of detergent residuals could be adopted such that residues should not exceed the detection limit of the method of analysis for the relevant active detergent substance. The effective removal of residues having pharmacological or toxicological activity is the primary concern in any cleaning procedure and validation of that procedure. In addition to chemical assay and microbiological testing, other tests, such as ph, TOC, and conductivity may be desirable. Whenever there is a change in manufacturing process, product formulation, manufacturing equipment, or cleaning procedure, revalidation of the cleaning procedure must be considered. Cleaning Standard Operating Procedure The standard cleaning operation procedure should include the following essential points: Objective Scope Describing the range of application for the SOP, equipment, and products. Responsibility Identification of who is responsible for performing the cleaning operations. Cleaning Validation 49

13 Procedure Description of cleaning method to be used including cleaning agent; concentration of the detergents surfactants, and sanitizing agents used during the cleaning procedure; temperature of the wash and rinse water or other solvent(s); flow rate and/or pressure at which the wash and rinse solvents are delivered; volume or amount of water or other solvents used to wash and rinse the equipment; diagrams describing the location of difficult to clean areas and trap points: inspection and/or testing regime to assess cleanliness and dryness; and status labeling of equipment and facility to ensure cleanliness status to all personnel. Other Items Additional concerns that should be considered in the cleaning SOP include the following: Where preparation of a cleaning solution is performed locally, it must be against a procedure that includes manufacturer instructions, batch numbering, and expiration dating. Training records of operators should be shown for each cleaning procedure. When a validated, automated cleaning procedure is in place, which produces a validated printout of critical processing stages, a triple check of critical stages should be performed. The validation review or re-validation status should be re-assessed based upon any changes to the operating situation, equipment replacement, cleaning procedure changes, regulatory requirements, or adverse market comments that are related to the cleaning validation. Re-validation should take place once a year at a minimum. The use of non-specific test methods could be permissible for re-validation exercises provided that the limits set can be related to a specific result in the initial validation or can be justified by some other means. Methods such as drain water conductivity and TOC analysis may be employed. Analytical Method The analytical method used to determine the residual amount of active should be validated. A proper performance qualification protocol and report should be appropriately established and approved prior to starting the cleaning procedure. This demonstrates that the laboratory equipment and techniques are capable of evaluating with precision, according to written and validated analytical methods, the small amount of residual contaminant (s) (active or others). A simulation exercise using the active product and the same material sur- 50 Institute of Validation Technology

14 face of production equipment would be suitable for the validation of the analytical method. Serial dilutions of active standard preparations could be used along with a placebo preparation containing the additives and excipients. These preparations would be suitable for simulating contamination during this exercise. Prior to the collection of samples from the cleaned equipment, it is important to prove the effectiveness of the swabbing method and the swab materials to be used. Cleaning Analytical Method Validation The following sections should be included: Objective Scope Describe the active product (s) that could be evaluated by the method. Acceptance Criteria Describe the method followed to determine the acceptance criteria. The major and critical acceptance criteria to be mentioned are as follows: active product recovery percentage and active residual (contaminant) µg per cm 2, or µg of active residual (contaminant) per maximum daily dose units of next product. Method Description of analytical methods used: standard preparation, sample preparation, analytical equipment used, analytical parameters, equipment parameter, sample volume, materials used, and the determination of the following values (which are specific to the analytical method and are relative for each active product): Precision Accuracy Limit of Detection Limit of Quantitation (LoQ) Linearity (where appropriate, linearity of detector response for standard solution over a range of concentrations) Recovery percentage Absence of interference between swab materials and active product Absence of interference between solvent and active product Cleaning Validation 51

15 Calculations Residual Limit of active (contaminant) A in mg / cm 2 of cleaned equipment or the concentration of active (contaminant) A carried over to unit dose of product B (contaminated) is calculated. Conclusion Cleaning Procedure Tools (Matrices) Tables, schemas, and matrices are the main tools used during the preparation of cleaning validation protocol and procedure especially for multi-product areas and equipment. This will help cleaning procedure developers to determine the worst-case and to calculate by the most efficient method the limit of contamination. Equipment Parts Schema Equipment parts schema are useful to illustrate the different critical parts of the equipment that are in direct contact with the product, parts area, location of difficult to clean areas or trap points, and swab locations. It contains equipment name, identification number (tag number), equipment location, name of each item, item surface, swab factor, and products to be manufactured in the machine. Products Type Matrix A table grouping the different active products according to their biological activity, physical characteristics, and toxicity should be established. This type of grouping gives an overview about the products manufacturing area and equipment to be used. Products having the same characteristics may require a dedicated facility or equipment. A product type matrix helps to choose appropriate cleaning procedures for each group of products. Based on this information, similar products should be gathered into one group. 52 Institute of Validation Technology

16 Figure 2 Equipment Parts Schema Cleaning Validation 53

17 Multi-Product Equipment Contamination Acceptance Criteria Matrix Where equipment is used for multi-products manufacturing, it is useful to establish a matrix listing the contamination acceptance limits of products compared to the worst-case. This matrix gives a quick overview about the maximum contaminant carryover per product (contaminant followed by contaminated). A, B, C, D, and E are the different products manufactured using the same equipment. Contaminant limit for each product expressed in µg / cm 2 is determined during the active product carryover acceptance criteria determination exercise. Values are reported properly in the matrix. For example, after manufacturing product D (contaminant), the equipment is cleaned according to the cleaning procedure then sampled (by swabs). Samples after analysis give the result of 18 µg / cm 2 as total residue of active product D (contaminant) in all product contact parts of the equipment. If the next product to be manufactured is B, the allowable limit of contamination figured in the matrix for this case (D followed by B) is 25 µg / cm 2. Consequently, the equipment will be declared clean and labeled accordingly. Cleaning validation matrices should be reviewed and revalidated following any change of cleaning elements e.g., modification of cleaning procedure, use of new equipment, and equipment modification could result in surface change of product contact parts, changes in regulatory requirements, introduction of new product, etc. 54 Institute of Validation Technology

18 Figure 3 Products Type Matrix * Given number to describe Biological Activity: 1, 2, 3, 4, 1 is more bioactive than 2, etc. ** Given number to describe Toxicity: 1, 2, 3, 4, 1 is more toxic than 2, etc. *** Given number to describe Solubility: 1, 2, 3, 4, 1 is more soluble than 2 in the same solvent, etc. Figure 4 Contamination Acceptance Criteria Matrix Cleaning Validation 55

19 Cleaning Procedure Flowchart Figure 5, summarizes the main steps of a cleaning procedure validation. Figure 5 Cleaning Procedures Validation Flowchart 1 1 No Cleaning Procedure Identification Establishing a rationale for the cleaning validation program OK? Yes Cleaning validation program is identified 2 2 Preparation of Cleaning Procedure (SOP) Define objectives, contamination limit approach, equipment and products group OK? No Yes Cleaning procedure ready to be validated 3 Preparation of Analytical Method Establish acceptance criteria Define sampling method Define analytical technique Establish acceptance criteria matrix OK? 3 No Yes Analytical method is validated 4 4 Cleaning Procedure Validation Procedure consistently meets acceptance criteria. Three consecutive, successful results. OK? No Yes Cleaning procedure is validated 2 Re- Validation Required Yes Is Change Critical? Change Control Routine Cleaning No 56 Institute of Validation Technology

20 CONCLUSION It is practically impossible to prove that production equipment is clean at the level of 100%. However, it is possible to prove that the traces of active product remaining, spread through the equipment parts, are within an acceptable limit and that we are capable of detecting and quantifying these trace levels. Cleaning validation provides a means of proving that the contamination levels have been reduced below contamination acceptance limits. The cleaning validation program should involve a rational monitoring program to maintain a validated state. Cleaning validation activity should cover active residue identification, active residue detection method selection, sampling method selection, the establishment of residue acceptance criteria, methods validation, recovery studies, and the identification of equipment parts in direct contact with the product. The good preparation and proper implementation of cleaning validation tools (matrices and tables) is a determinant factor in the success of a cleaning validation program. About the Author Mowafak Nassani Ph.D. has a Doctoral degree from U.S.T.L. University of Montpellier, France, in Analytical, Industrial Chemistry. He is the General Director of Pharmaceutical Validation Services at PVS Canada. He worked as a senior consultant in QA/QC, GMP, compliance, auditing and validation for I.C.C.E, Brussels, Belgium. He has occupied the post of QA/QC Manager in leading multinational pharmaceutical companies. Dr. Nassani can be reach by phone at: +1 (514) or by at: mnassani@pharmavs.com Cleaning Validation 57

21 REFERENCES 1. Guidance for Industry, Non-clinical Studies for the Safety Evaluation of Pharmaceutical Excipients, 5/18/ FDA, Guide to Inspection of Validation of Cleaning Processes, July International Conference on Harmonization (ICH), Guidance for Industry: Q3A Impurities in New Drug Substances, 2/11/ Validation of Analytical Procedures: Methodology, FDA Guidance, December FDA, Guide to Inspection of Pharmaceutical Quality Control Laboratories, July Article Acronym Listing cfu cgmp CIP FDA HPLC ICH LD/LoD LoQ ppm QA QC SOP TOC UV WFI Colony Forming Unit Current Good Manufacturing Practice Clean-In-Place Food and Drug Administration High Performance Liquid Chromatography International Conference on Harmonization Limit of Detection Limit of Quantitation Parts per million Quality Assurance Quality Control Standard Operating Procedure Total Organic Carbon Ultra Violet Water-For-Injection Originally published in the August 2005 issue of the Journal of Validation Technology 58 Institute of Validation Technology

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current

More information

Cleaning validation of cleanrooms and preparation equipments

Cleaning validation of cleanrooms and preparation equipments Cleaning validation of cleanrooms and preparation equipments Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About Compounding" 23-25 May,

More information

Systems-Based Inspections for Cleaning Validation

Systems-Based Inspections for Cleaning Validation Systems-Based Inspections for Cleaning Validation FDA DG 230 December 8, 2014 Rockville, MD Destin A. LeBlanc Cleaning Validation Technologies www.cleaningvalidation.com 1 Objectives Describe and/or identify:

More information

Analytical Methods for Cleaning Validation

Analytical Methods for Cleaning Validation Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2011, 3 (6): 232-239 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

Implementing New USP Chapters for Analytical Method Validation

Implementing New USP Chapters for Analytical Method Validation Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: Ludwig_Huber@labcompliance.com Today s Agenda Handling Method Changes vs. Adjustments

More information

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS. GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au

More information

Cleaning Validation. Objectives. Critical cleaning? Cleaning. Non-critical cleaning? Life Cycle Approach

Cleaning Validation. Objectives. Critical cleaning? Cleaning. Non-critical cleaning? Life Cycle Approach Cleaning Validation FDA Basic Drug School June 28, 2012 Chicago, IL Destin A. LeBlanc Cleaning Validation Technologies www.cleaningvalidation.com destin@cleaningvalidation.com 1 Objectives Define terminology

More information

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories

More information

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:

More information

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY

More information

Guidance on aspects of cleaning validation in active pharmaceutical ingredient plants

Guidance on aspects of cleaning validation in active pharmaceutical ingredient plants Guidance on aspects of cleaning validation in active pharmaceutical ingredient plants December 2000 A Sector Group of CEFIC Table of Contents 1.0 FOREWORD 3 2.0 OBJECTIVE 3 3.0 SCOPE 3 4.0 ACCEPTANCE CRITERIA

More information

Microbiology and Auditing. Don Singer

Microbiology and Auditing. Don Singer Microbiology and Auditing Don Singer ASQ Northeast Pharmaceutical GMP/Quality Conference 2011 Through the eyes of a Microbiologist Microbiology Audit = Inspection / Investigation Systematic Auditing Planning

More information

Annex 4 Supplementary guidelines on good manufacturing practices: validation

Annex 4 Supplementary guidelines on good manufacturing practices: validation World Health Organization WHO Technical Report Series, No. 937, 2006 Annex 4 Supplementary guidelines on good manufacturing practices: validation 1. Introduction 2. Scope 3. Glossary 4. Relationship between

More information

Validation and Calibration. Definitions and Terminology

Validation and Calibration. Definitions and Terminology Validation and Calibration Definitions and Terminology ACCEPTANCE CRITERIA: The specifications and acceptance/rejection criteria, such as acceptable quality level and unacceptable quality level, with an

More information

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services

More information

To avoid potential inspection

To avoid potential inspection Good Analytical Method Validation Practice Deriving Acceptance for the AMV Protocol: Part II To avoid potential inspection observations for test method validations by the regulatory agencies, it has become

More information

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5 European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control

More information

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 *

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 * PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/INF 11/2015 1 April 2015 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 * * Entry into force:

More information

Highly Potent APIs The right platform, people and procedures for successful development and manufacturing

Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Pharma&Biotech Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Custom Manufacturing and Development Services for Highly Potent APIs Pharma&Biotech

More information

IMPURITIES IN NEW DRUG PRODUCTS

IMPURITIES IN NEW DRUG PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current

More information

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical

More information

Risk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI

Risk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI Risk-Based Environmental Monitoring Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI Presenter Marsha Stabler Hardiman Over 20 years experience in the

More information

FDA and the Compounding Pharmacy

FDA and the Compounding Pharmacy FDA and the Compounding Pharmacy Scott Sutton, Ph.D. scott.sutton@microbiol.org 41 Overview of Presentation The Recent Events GCP and GMP Basics the 483 Review H.R. 3204 Outsourcing Facility Preparation

More information

SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION

SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTE Working document QAS/03.055/Rev.2 RESTRICTED SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION This document has followed

More information

Hazard Analysis and Critical Control Points (HACCP) 1 Overview

Hazard Analysis and Critical Control Points (HACCP) 1 Overview Manufacturing Technology Committee Risk Management Working Group Risk Management Training Guides Hazard Analysis and Critical Control Points (HACCP) 1 Overview Hazard Analysis and Critical Control Point

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):892-898 World Health Organization s Guidelines for

More information

3.4 TEST FOR BACTERIAL ENDOTOXINS. Final text for revision of The International Pharmacopoeia

3.4 TEST FOR BACTERIAL ENDOTOXINS. Final text for revision of The International Pharmacopoeia Document QAS/11.5 FINAL July 01 3. TEST FOR BACTERIAL ENDOTOXINS Final text for revision of The International Pharmacopoeia This monograph was adopted at the Forty-sixth WHO Expert Committee on Specifications

More information

RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009

RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009 RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009 This resolution provides for the alteration, inclusion, suspension, reactivation and cancellation after registration of medications and sets forth other provisions.

More information

Cleaning. By the end of this chapter, you will be able to: Introduction. Definitions. Chapter 9

Cleaning. By the end of this chapter, you will be able to: Introduction. Definitions. Chapter 9 Chapter 9 By the end of this chapter, you will be able to: l Define the terms cleaning, decontamination, disinfection l List the factors that affect disinfection l Describe the aims of a cleaning schedule

More information

Cleaning and Contamination Control

Cleaning and Contamination Control Cleaning and Contamination Control A regulatory perspective Lynn Talomsin Senior Inspector, Manufacturing Quality Branch, TGA Control Practices Cleaning and Contamination Control Contamination control

More information

Workshop B Control Strategy

Workshop B Control Strategy ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation

More information

EudraLex. The Rules Governing Medicinal Products in the European Union Volume 4

EudraLex. The Rules Governing Medicinal Products in the European Union Volume 4 Ref. Ares(2015)283695-23/01/2015 PT CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy EudraLex

More information

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance

More information

Design of Experiments for Analytical Method Development and Validation

Design of Experiments for Analytical Method Development and Validation Design of Experiments for Analytical Method Development and Validation Thomas A. Little Ph.D. 2/12/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com

More information

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 In-process control In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 Here you will find answers to the following questions: What are the in-process control tasks? Where

More information

Library Guide: Pharmaceutical GMPs

Library Guide: Pharmaceutical GMPs Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA

More information

Expectations for Data to Support Clinical Trial Drugs

Expectations for Data to Support Clinical Trial Drugs Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief

More information

GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS

GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE DRAFT CONSENSUS GUIDELINE GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL

More information

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external

More information

Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals

Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals 1. Introduction Traditionally,

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION

More information

FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts UNDERSTANDING WHAT IS NEEDED TO PRODUCE QUALITY DATA

FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts UNDERSTANDING WHAT IS NEEDED TO PRODUCE QUALITY DATA FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts UNDERSTANDING WHAT IS NEEDED TO PRODUCE QUALITY DATA The NFL White Paper Series Volume 7, January 2013 Overview and a Scenario With so

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products European Medicines Agency June 2005 CPMP/ICH/5721/03 ICH Topic Q 5 E Comparability of Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS SUBJECT TO CHANGES

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc.

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration & Preventative Maintenance Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration: A comparison of two instruments or measuring devices one of which is a standard of known

More information

PDA Technical Report No. 29 Points to Consider for Cleaning Validation

PDA Technical Report No. 29 Points to Consider for Cleaning Validation PDA Technical Report No. 29 Points to Consider for Cleaning Validation DRAFT March 30, 1998 TR28_002.PDF PDA Pharmaceutical Cleaning Validation Task Force James P. Agalloco, Agalloco & Associates Will

More information

DISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION

DISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION 1 US FDA Form 483: A Case Study DISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION DEVELOPED BY FRAN RABE 2 Introduction This case study is intended to extract portions of information

More information

Technical Guidance Manual for the Implementation of the Hawai`i State Contingency Plan. Interim Final SECTION 10

Technical Guidance Manual for the Implementation of the Hawai`i State Contingency Plan. Interim Final SECTION 10 Technical Guidance Manual for the Implementation of the Hawai`i State Contingency Plan SECTION 10 DATA QUALITY ASSURANCE AND QUALITY CONTROL (QA/QC) Hawai`i HEER TGM 10-1 December 31, 2008 CONTENTS Acronyms

More information

Guideline on Process Validation

Guideline on Process Validation 1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /

More information

1 Quality Assurance and Quality Control Project Plan

1 Quality Assurance and Quality Control Project Plan 1 Quality Assurance and Quality Control Project Plan The purpose of this section is to describe the quality assurance/quality control program that will be used during the system specific field testing

More information

Process Validation: Practical Aspects of the New FDA Guidance

Process Validation: Practical Aspects of the New FDA Guidance Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory

More information

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER DISCUSSION IN THE HMPWG 2003-2005 RELEASE FOR CONSULTATION December 2005 DEADLINE

More information

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,

More information

Qualification of an Environmental Monitoring Program

Qualification of an Environmental Monitoring Program [ Scott Sutton Qualification of an Environmental Monitoring Program Scott Sutton Microbiology Topics discusses various topics in microbiology of practical use in validation and compliance. We intend this

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL

More information

A Stability Program for the Distribution of Drug Products

A Stability Program for the Distribution of Drug Products A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal

More information

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/380/95 ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

More information

Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate

Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate Cantaurus, Vol. 7, 5-8, May 1999 McPherson College Division of Science and Technology Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate Janet Bowen ABSTRACT Sulfate is used in

More information

EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS

EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS BIOGRAPHICAL NOTE Kurt Moyer, Ph.D. Director of Research, NSF Pharmalytica Bristol, Connecticut, USA 06010 Tel: 1(860)

More information

Overview of Drug Development: the Regulatory Process

Overview of Drug Development: the Regulatory Process Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger

More information

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)

More information

Statistical estimation using confidence intervals

Statistical estimation using confidence intervals 0894PP_ch06 15/3/02 11:02 am Page 135 6 Statistical estimation using confidence intervals In Chapter 2, the concept of the central nature and variability of data and the methods by which these two phenomena

More information

Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination of Sodium Alginate from Oral Suspension

Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination of Sodium Alginate from Oral Suspension International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.2, No.2, pp 1634-1638, April-June 2010 Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination

More information

Chapter 7 Equipment and Utensil Cleaning and Sanitization

Chapter 7 Equipment and Utensil Cleaning and Sanitization Chapter 7 Equipment and Utensil Cleaning and Sanitization The importance of proper cleaning can be appreciated when one realizes that contaminated equipment (equipment and utensils which are not clean)

More information

Revision of The Dissolution Procedure: Development and Validation 1092

Revision of The Dissolution Procedure: Development and Validation 1092 Page 1 of 5 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Revision of The Dissolution Procedure: Development and Validation

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

USP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants

USP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants USP Pharmaceutical Ingredient Supplier Qualification Program Manual for Participants UNITED STATES PHARMACOPEIA Drug Substance Supplier Qualification Program ICE This manual provides information to drug

More information

BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use.

BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use. BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use. USP proposes the revision and development of a suite of plastic packaging system standards in the current issue of PF. General test chapter

More information

PHARMACEUTICAL REFERENCE STANDARDS

PHARMACEUTICAL REFERENCE STANDARDS PHARMACEUTICAL REFERENCE STANDARDS 11 th International Symposium organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 3-4 September 2012, Strasbourg,

More information

BY UV SPECTROPHOTOMETRY

BY UV SPECTROPHOTOMETRY 1 of 9 1. PURPOSE This Standard Operating Procedure describes the method for measuring the concentration of viral particles using UV/Vis spectrophotometry at 260 and 280 nm. 2. SCOPE This procedure is

More information

Changes to an Approved Product

Changes to an Approved Product Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved

More information

White paper: FDA Guidance for Industry Update Process Validation

White paper: FDA Guidance for Industry Update Process Validation White paper: FDA Guidance for Industry Update Process Validation In January 2011, the FDA released the final version of its long-awaited update to its Process Validation Guidance for Industry. Since then,

More information

Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers

Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof; DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of

More information

CONCEPTS OF FOOD SAFETY QUALITY MANAGEMENT SYSTEMS. Mrs. Malini Rajendran

CONCEPTS OF FOOD SAFETY QUALITY MANAGEMENT SYSTEMS. Mrs. Malini Rajendran CONCEPTS OF FOOD SAFETY AND QUALITY MANAGEMENT SYSTEMS Mrs. Malini Rajendran Brief background 1963 - The Codex Alimentarius Commission was created by FAO and WHO to develop food standards, guidelines and

More information

Online Total Organic Carbon (TOC)

Online Total Organic Carbon (TOC) Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE January/February 2008, Vol. 29 No. 1 This article offers an alternative method to cleaning validation using online total organic

More information

Ecology Quality Assurance Glossary

Ecology Quality Assurance Glossary Ecology Quality Assurance Glossary Edited by William Kammin, Ecology Quality Assurance Officer Accreditation - A certification process for laboratories, designed to evaluate and document a lab s ability

More information

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address: NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a

More information

TSI BIOTRAK REAL-TIME VIABLE PARTICLE COUNTER FACILITY MONITORING SYSTEMS

TSI BIOTRAK REAL-TIME VIABLE PARTICLE COUNTER FACILITY MONITORING SYSTEMS TSI BIOTRAK REAL-TIME VIABLE PARTICLE COUNTER FACILITY MONITORING SYSTEMS APPLICATION NOTE CC-105 (US) Introduction This application note will demonstrate how real-time viable particle count data will

More information

ACO Cleaning principles for drainage

ACO Cleaning principles for drainage Cleaning procedures ACO Cleaning principles for drainage Page Introduction 3 Principles of cleaning 4 Cleaning procedures ACO cleaning principles for drainage Cleaning chemicals 5 Manual cleaning of drainage

More information

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients Not for publication. This draft text is for circulation for approval by the Joint Committee and has not been published or otherwise officially promulgated. All rights reserved. This document may be reproduced

More information

Valentina Gualato, Ph.D. Process Development Scientist

Valentina Gualato, Ph.D. Process Development Scientist COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing

More information

Cleaning Validation by TOC Analyzer

Cleaning Validation by TOC Analyzer LAAN-A-TC-E017 Total Organic Carbon Analysis No.O41 Cleaning Validation by TOC Analyzer To ensure quality control and safety in manufacturing facilities within the pharmaceutical industry, it is important

More information

GUIDANCE ON ASPECTS OF CLEANING VALIDATION

GUIDANCE ON ASPECTS OF CLEANING VALIDATION ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE (APIC) GUIDANCE ON ASPECTS OF CLEANING VALIDATION IN ACTIVE PHARMACEUTICAL INGREDIENT PLANTS May 2014 1 Table of Contents 1.0 FOREWORD 2.0 OBJECTIVE 3.0 SCOPE

More information

Intelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection

Intelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection 52 May/June 2012 Intelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection by Karen Rome and Allyson McIntyre, AstraZeneca, Macclesfield, SK10 2NA, UK Quantitative analysis

More information

Guidance on Qualification of existing facilities, systems, equipment and utilities

Guidance on Qualification of existing facilities, systems, equipment and utilities QUALIFICATION_EXISTING_EQUIPMENT_FINAL page 1 / 16 1. Acknowledgement...3 2. Introduction...3 3. Scope...4 4. Regulatory requirements...4 5. Guidance...4 5.1 Risk Assessment... 4 5.2 Procedure... 7 5.3

More information

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC

More information

Blood, Plasma, and Cellular Blood Components INTRODUCTION

Blood, Plasma, and Cellular Blood Components INTRODUCTION Blood, Plasma, and Cellular Blood Components INTRODUCTION This chapter of the Guideline provides recommendations to Sponsors of Requests for Revision for new monographs for blood, plasma, and cellular

More information

LC-MS/MS, the new reference method for mycotoxin analysis

LC-MS/MS, the new reference method for mycotoxin analysis LC-MS/MS, the new reference method for mycotoxin analysis What is necessary for the implementation of the multi-residue mycotoxin method in an analytical laboratory? Azel Swemmer azel@fdalab.co.za AFMA

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:

More information

Vitamin C quantification using reversed-phase ion-pairing HPLC

Vitamin C quantification using reversed-phase ion-pairing HPLC Vitamin C quantification using reversed-phase ion-pairing HPLC Thomas Grindberg and Kristy Williams Department of Chemistry, Concordia College, 901 8 th St S, Moorhead, MN 56562 Abstract Vitamin C, an

More information

Recent Updates on European Requirements and what QPs are expected to do

Recent Updates on European Requirements and what QPs are expected to do Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status

More information

JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS

JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS 1 WHAT IS A SITE MASTER FILE? A Site Master File (SMF) is a document prepared by the manufacturer containing specific

More information

The use of risk assessment tools for microbiological assessment of cleanroom environments. by Tim Sandle

The use of risk assessment tools for microbiological assessment of cleanroom environments. by Tim Sandle The use of risk assessment tools for microbiological assessment of cleanroom environments by Tim Sandle Email: tim.sandle@bpl.co.uk / timsandle@btinternet.com Web: www.pharmig.blogspot.com Environmental

More information